Navigation Links
ULURU Inc. Reports Third Quarter 2007 Results
Date:11/13/2007

ADDISON, Texas, Nov. 13 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) reported financial results today for the quarter and nine months ended September 30, 2007.

For the quarter ended September 30, 2007, the net loss attributable to common stockholders was $1,240,000, or $0.02 per share, compared to a net loss of $3,994,000, or $0.31 per share, for the corresponding period in 2006. For the nine months ended September 30, 2007, the net loss attributable to common stockholders was $3,296,000, or $0.05 per share, compared to a net loss of $8,524,000, or $0.70 per share, for the nine months ended September 30, 2006. The net loss was impacted by non-cash expenses related to stock options accounted for in accordance with SFAS 123(R) "Share Based Payment" of $140,000 and $361,000, for the quarter and nine months ended September 30, 2007, respectively, (compared with no expense for the corresponding periods in 2006) and by the amortization of our intangible assets of $272,000 and $806,000 for the quarter and nine months ended September 30, 2007, respectively.

Income Statement

Revenues for the third quarter of 2007 were $130,000, compared with $113,000 for the same period last year. The overall increase of $17,000 is primarily due to increased licensing fees of $14,000 for OraDisc(TM) B and increased sponsored research of $21,000. These positive factors were partially offset by a decrease in royalties for the third quarter of 2007 associated with the international sales of Zindaclin(R) due to product launches in 2006.

Total costs and expenses increased by $546,000 in the third quarter of 2007 to $1,567,000, compared with the corresponding period in 2006 where total costs and expenses were $1,021,000. General and administrative expenses were primarily responsible for the increase, as these expenses increased from $351,000 in the second quarter 2006 to $821,000 in 2007, a $470,000 increase. Increased costs include legal expenses for patent pros
'/>"/>

SOURCE ULURU Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. Haemacure Reports Third Quarter 2007 Results
6. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. MDS Reports Third Quarter 2007 Results
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...O, May 12 /PRNewswire-FirstCall/ - Med-Emerg Inter... revenue from continuing operations,for the three...pared to,$4.8 million for the same period in 2007 ... the three month period, earnings before,depreciat...roved to $179K,from a loss of ($106K) in 2007. The...
(Date:5/12/2008)...D, Calif., May 12 /PRNewswire-FirstCall/ -- (Nasda...Heart" or the "Corporation") announced,that the To...ay advising it,is reviewing the eligibility for co... WorldHeart under sections 709 and 710(a) of the T...any,s financial condition and,operating results, m...
(Date:5/12/2008)...ONT, Calif., May 12 /PRNewswire/ -- Keck Graduate ...008, commencement ceremony will feature,the gradua...tudent, Eric,Tan, and the unveiling of KGI,s first... of Eric,s achievement in becoming the,first gradu..., KGI,s senior,vice president for academic affairs...
(Date:5/12/2008)...LE, N.Y., May 12 /PRNewswire/ -- Fairbank Farms, a...tary recall of selected ground beef,products produ...gh Price,Chopper, Shaw,s, BJ,s, and Wilson Farms r... affected product may contain small pieces of hard...l-by" date of 05/13/08, 05/15/08, or a,"Julian dat...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. reports improved income from continuing operations 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 3Health News:WorldHeart Notified of TSX Delisting Review 2Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2Health News:Fairbank Farms Issues Voluntary Recall for Selected Ground Beef Products 2
...tudy published in the February issue of the Journa... infection does raise the risk of developing preec...also indicate that preeclamptic mothers have low b... who do not have preeclampsia. "We found that chro...
...receive protection from respiratory illness as a r...hantry led research study. As many as 2,277 childr...ths were studied during the course of the research...ly, full breastfeeding for less than one month, fu...
...pt increase in the case of uterine cancer among ol...ates increasing due to better // treatment and d... has been witnessed across Europe. Some of the rea... early puberty, and higher body weight. Overweig...
...d researchers are reported to identified two drugs...otect monkeys from contracting the AIDS virus. // ...ngs also has not yet been confirmed, even though i...re experimented upon by the Centers for Disease an...
Other Medicine News:Health News:Gum Disease Associated With Increased Risk of Preeclampsia 2
(Date:5/9/2008)...USNewswire/ -- Osteoarthritis is a,painful and pot...t 50,million people in the United States. It is ca... The novel investigational pain medication,tapenta...ignificant relief,for patients with joint-disease ...with fewer gastrointestinal side effects than thos...
(Date:5/9/2008)...ewswire/ -- The risk of the two major,prostate dis...H), can be,reduced by changes in lifestyle, such a...d eating a healthy diet. Alan Kristal, Dr.P.H., as...red Hutchinson Cancer Research,Center in Seattle, ...ot,feel helpless against prostate cancer or BPH.,...
(Date:5/9/2008)...Study Shows Positive Results with X-ray ... /- Roche today announced one-year,re...that ACTEMRA(TM),(tocilizumab) can significantly i...in patients with rheumatoid arthritis (RA), a crit...The study also demonstrated that ACTEMRA,reduces d...
(Date:5/8/2008)...lobus Medical, Inc., the largest,privately held sp...nized,leader in motion preservation technology, to...SECURE(R)-C Cervical Artificial Disc IDE study. Th...al motion of the spine in,order to alleviate pain ...n,the treatment of symptomatic cervical disc disea...
Breaking Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 2Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 3Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Mislabeled Supplement Spurred Prostate Cancer 3A Report 9792 1Mislabeled Supplement Spurred Prostate Cancer 3A Report 9792 2Mislabeled Supplement Spurred Prostate Cancer 3A Report 9792 3Gift of Life Celebrates Saving Lives and Setting Records in 2007 9788 1Gift of Life Celebrates Saving Lives and Setting Records in 2007 9788 2Gift of Life Celebrates Saving Lives and Setting Records in 2007 9788 3Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday January 24 2008 9784 1Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday January 24 2008 9784 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage Eli Lilly and Company issued the following 2665 1In response to a New England Journal of Medicine article published yesterday and subsequent media coverage Eli Lilly and Company issued the following 2665 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage Eli Lilly and Company issued the following 2665 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage Eli Lilly and Company issued the following 2665 4
The KM-500's unique viewing and alignment window lets you observe the targeted eye from any distance. Two rechargeable batteries provide continuous uninterrupted use. Each battery provides 60 minutes
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus.
Provides quick freezing and quick defrosting by reversible flow of gas system - cleans the probes for every cycle automatically. Lightweight probe tips have high conductivity silver. Useful for Catar
...y reversible flow of gas system - cleans the probe... tips have high conductivity silver. Single footsw...r of the two by a simple selector switch. Surgeon ...and Aspiration together with the double footswitch...
Medicine Products: